DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/ctgjz8/il5_signaling) has announced the addition of the "IL-5 Signaling Pathway in Oncology Drug Pipeline Update 2014" report to their offering.
The IL-5 singaling pathway activates the JAK/STAT and Raf/MAPK signaling modules.
There are today 121 companies plus partners developing 162 IL-5 pathway targeting drugs in 642 developmental projects in cancer. In addition, there is 1 suspended drug and the accumulated number of ceased drugs over the last years amount to another 64 drugs.
Il-5 Signaling Pathway In Oncology Drug Pipeline Update lists all drugs and gives you a progress analysis on each one of them. Identified drugs are linked to 136 different targets. All included targets have been cross-referenced for the presence of mutations associated with human cancer. To date 133 out of the 135 studied drug targets so far have been recorded with somatic mutations.
The software application lets you narrow in on these mutations and links out to the mutational analysis for each of the drug targets for detailed information. All drugs targets are further categorized on in the software application by 31 classifications of molecular function and with pathway referrals to BioCarta, KEGG, NCI-Nature and NetPath.
How May Drug Pipeline Update Be of Use?
- Show investors/board/management that you are right on top of drug development progress in your therapeutic area.
- Find competitors, collaborations partners, M&A candidates etc
- Jump start competitive drug intelligence operations
- Excellent starting point for world wide benchmarking
-
Compare portfolio and therapy focus with your peers
- Speed up pro-active in-/out licensing strategy work
Pipeline Breakdown According to Number of Drugs
- Marketed # 10
- Pre-registration # 1
- Phase III # 18
- Phase II # 64
- Phase I # 88
- Preclinical # 72
- No Data # 4
- Suspended # 1
- Ceased # 64
For more information visit http://www.researchandmarkets.com/research/ctgjz8/il5_signaling
